June 28, 2017
1 pm to 2 pm EDT

Sponsored by



Webinar Description:

In this Webinar Kevin Hrusovskly, the CEO and Chairman of Quanterix will discuss the use of ultrasensitive biomarker assays to enable precision health. Kevin will describe the use of Simoa technology to not only detect disease but be able to monitor normal biology which is enabling a transformation in medicine from "sick care" to "health care". Kevin will be joined in this webinar by Dr. Henrik Zetterberg who will provide specific examples of the use of biomarkers to detect neuro degeneration, and Dr. Jessica Gill who will discuss data showing correlation of biomarker levels to neurotrauma.


Kevin HrusovskyKevin Hrusovsky

Executive Chairman and Chief Executive Officer


Kevin joined Quanterix in 2014 and serves as the Chief Executive Officer and Executive Chairman. With over 25 years of experience in the life sciences space, he has dedicated his career to transforming healthcare into personalized medicine, and has a proven track record of commercializing disruptive technologies. Kevin currently serves on the Board of Directors of several companies transforming the future of precision health.

Jessica GillDr. Jessica Gill, Ph.D., R.N.

Investigator at National Institutes of Health (NIH)
Co-director of the biomarkers core for the Center for Neurosciences and Regenerative Medicine


Dr. Gill is an investigator at National Institutes of Health (NIH) and co- director of the biomarkers core for the Center for Neurosciences and Regenerative Medicine. Her work examines biological mechanisms of traumatic brain injury (TBI), and related co-morbidities including post- traumatic stress disorder (PTSD), post-concussive disorder (PCD), depression and neurological deficits. Dr. Gill’s studies include alterations in tau and amyloid beta in acute and chronic TBI patients using the SIMOA system. Collaborations include analyses of epigenetic modifications in athletes with repeated TBIs, as gene- expression changes related to neuronal imaging findings, and relations to PCD symptoms. She is a Lasker Clinical Research Scholar Recipient.

Henrik ZetterbergDr. Henrik Zetterberg

Dr. Henrik Zetterberg, Professor of Neurochemistry and Head of Department at University of Gothenburg, Professor of Neurochemistry at University College London and Senior Consultant in Clinical Chemistry at Sahlgrenska University Hospital. His main research interest is fluid biomarkers for CNS disorders